CD4 and neoplasm: There is also evidence that PD-L1-expressing TCR gamma delta (γδ) T cells can abrogate the tumor-directed activity of CD4 and CD8 T cells, which can be reversed by immune checkpoint blockade using anti-PD-L1 antibodies (34).